Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Elora Gupta

AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Rizvi NA, Humphrey JS, Ness EA, Johnson MD, Gupta E, Williams K, Daly DJ, Sonnichsen D, Conway D, Marshall J, Hurwitz H. A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin Cancer Res. 2004 Mar 15; 10(6):1963-70. PMID: 15041713.
      View in: PubMed
    2. Klein CE, Gupta E, Reid JM, Atherton PJ, Sloan JA, Pitot HC, Ratain MJ, Kastrissios H. Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide. Clin Pharmacol Ther. 2002 Dec; 72(6):638-47. PMID: 12496745.
      View in: PubMed
    3. Plummer R, Ghielmini M, Calvert P, Voi M, Renard J, Gallant G, Gupta E, Calvert H, Sessa C. Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies. Clin Cancer Res. 2002 Sep; 8(9):2788-97. PMID: 12231518.
      View in: PubMed
    4. Gupta E, Mick R, Ramirez J, Wang X, Lestingi TM, Vokes EE, Ratain MJ. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol. 1997 Apr; 15(4):1502-10. PMID: 9193346.
      View in: PubMed
    5. Gupta E, Wang X, Ramirez J, Ratain MJ. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol. 1997; 39(5):440-4. PMID: 9054958.
      View in: PubMed
    6. Mick R, Gupta E, Vokes EE, Ratain MJ. Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity. J Clin Oncol. 1996 Jul; 14(7):2012-9. PMID: 8683231.
      View in: PubMed
    7. Gupta E, Safa AR, Wang X, Ratain MJ. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A. Cancer Res. 1996 Mar 15; 56(6):1309-14. PMID: 8640819.
      View in: PubMed
    8. Roy SK, Gupta E, Dolan ME. Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. Drug Metab Dispos. 1995 Dec; 23(12):1394-9. PMID: 8689950.
      View in: PubMed
    9. Gupta E, Olopade OI, Ratain MJ, Mick R, Baker TM, Berezin FK, Benson AB, Dolan ME. Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent. Clin Cancer Res. 1995 Oct; 1(10):1133-8. PMID: 9815904.
      View in: PubMed
    10. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 1994 Jul 15; 54(14):3723-5. PMID: 8033091.
      View in: PubMed
    Gupta's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Physical Neighbors Expand Description
    _